EGFR-mutated lung cancer: a paradigm of molecular oncology.

Zhenfeng Zhang, Amy L. Stiegler, Titus J. Boggon, Susumu Kobayashi, Balazs Halmos

Research output: Contribution to journalReview article

134 Citations (Scopus)

Abstract

The development of EGFR tyrosine kinase inhibitors for clinical use in non-small cell lung cancer and the subsequent discovery of activating EGFR mutations have led to an explosion of knowledge in the fields of EGFR biology, targeted therapeutics and lung cancer research. EGFR-mutated adenocarcinoma of the lung has clearly emerged as a unique clinical entity necessitating the routine introduction of molecular diagnostics into our current diagnostic algorithms and leading to the evidence-based preferential usage of EGFR-targeted agents for patients with EGFR-mutant lung cancers. This review will summarize our current understanding of the functional role of activating mutations, key downstream signaling pathways and regulatory mechanisms, pivotal primary and acquired resistance mechanisms, structure-function relationships and ultimately the incorporation of molecular diagnostics and small molecule EGFR tyrosine kinase inhibitors into our current treatment paradigms.

Original languageEnglish (US)
Pages (from-to)497-514
Number of pages18
JournalOncotarget
Volume1
Issue number7
StatePublished - Nov 2010
Externally publishedYes

Fingerprint

Molecular Pathology
Protein-Tyrosine Kinases
Lung Neoplasms
Mutation
Explosions
Proxy
Non-Small Cell Lung Carcinoma
Therapeutics
Research
Adenocarcinoma of lung

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Zhang, Z., Stiegler, A. L., Boggon, T. J., Kobayashi, S., & Halmos, B. (2010). EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget, 1(7), 497-514.

EGFR-mutated lung cancer : a paradigm of molecular oncology. / Zhang, Zhenfeng; Stiegler, Amy L.; Boggon, Titus J.; Kobayashi, Susumu; Halmos, Balazs.

In: Oncotarget, Vol. 1, No. 7, 11.2010, p. 497-514.

Research output: Contribution to journalReview article

Zhang, Z, Stiegler, AL, Boggon, TJ, Kobayashi, S & Halmos, B 2010, 'EGFR-mutated lung cancer: a paradigm of molecular oncology.', Oncotarget, vol. 1, no. 7, pp. 497-514.
Zhang Z, Stiegler AL, Boggon TJ, Kobayashi S, Halmos B. EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget. 2010 Nov;1(7):497-514.
Zhang, Zhenfeng ; Stiegler, Amy L. ; Boggon, Titus J. ; Kobayashi, Susumu ; Halmos, Balazs. / EGFR-mutated lung cancer : a paradigm of molecular oncology. In: Oncotarget. 2010 ; Vol. 1, No. 7. pp. 497-514.
@article{4edfd8ed29a44feeba7bca34e164b9b2,
title = "EGFR-mutated lung cancer: a paradigm of molecular oncology.",
abstract = "The development of EGFR tyrosine kinase inhibitors for clinical use in non-small cell lung cancer and the subsequent discovery of activating EGFR mutations have led to an explosion of knowledge in the fields of EGFR biology, targeted therapeutics and lung cancer research. EGFR-mutated adenocarcinoma of the lung has clearly emerged as a unique clinical entity necessitating the routine introduction of molecular diagnostics into our current diagnostic algorithms and leading to the evidence-based preferential usage of EGFR-targeted agents for patients with EGFR-mutant lung cancers. This review will summarize our current understanding of the functional role of activating mutations, key downstream signaling pathways and regulatory mechanisms, pivotal primary and acquired resistance mechanisms, structure-function relationships and ultimately the incorporation of molecular diagnostics and small molecule EGFR tyrosine kinase inhibitors into our current treatment paradigms.",
author = "Zhenfeng Zhang and Stiegler, {Amy L.} and Boggon, {Titus J.} and Susumu Kobayashi and Balazs Halmos",
year = "2010",
month = "11",
language = "English (US)",
volume = "1",
pages = "497--514",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "7",

}

TY - JOUR

T1 - EGFR-mutated lung cancer

T2 - a paradigm of molecular oncology.

AU - Zhang, Zhenfeng

AU - Stiegler, Amy L.

AU - Boggon, Titus J.

AU - Kobayashi, Susumu

AU - Halmos, Balazs

PY - 2010/11

Y1 - 2010/11

N2 - The development of EGFR tyrosine kinase inhibitors for clinical use in non-small cell lung cancer and the subsequent discovery of activating EGFR mutations have led to an explosion of knowledge in the fields of EGFR biology, targeted therapeutics and lung cancer research. EGFR-mutated adenocarcinoma of the lung has clearly emerged as a unique clinical entity necessitating the routine introduction of molecular diagnostics into our current diagnostic algorithms and leading to the evidence-based preferential usage of EGFR-targeted agents for patients with EGFR-mutant lung cancers. This review will summarize our current understanding of the functional role of activating mutations, key downstream signaling pathways and regulatory mechanisms, pivotal primary and acquired resistance mechanisms, structure-function relationships and ultimately the incorporation of molecular diagnostics and small molecule EGFR tyrosine kinase inhibitors into our current treatment paradigms.

AB - The development of EGFR tyrosine kinase inhibitors for clinical use in non-small cell lung cancer and the subsequent discovery of activating EGFR mutations have led to an explosion of knowledge in the fields of EGFR biology, targeted therapeutics and lung cancer research. EGFR-mutated adenocarcinoma of the lung has clearly emerged as a unique clinical entity necessitating the routine introduction of molecular diagnostics into our current diagnostic algorithms and leading to the evidence-based preferential usage of EGFR-targeted agents for patients with EGFR-mutant lung cancers. This review will summarize our current understanding of the functional role of activating mutations, key downstream signaling pathways and regulatory mechanisms, pivotal primary and acquired resistance mechanisms, structure-function relationships and ultimately the incorporation of molecular diagnostics and small molecule EGFR tyrosine kinase inhibitors into our current treatment paradigms.

UR - http://www.scopus.com/inward/record.url?scp=79958020132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958020132&partnerID=8YFLogxK

M3 - Review article

C2 - 21165163

AN - SCOPUS:79958020132

VL - 1

SP - 497

EP - 514

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 7

ER -